Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Up 188.0% in August

Key Points

• Inventiva S.A. Sponsored ADR (NASDAQ:IVA) experienced a remarkable increase in short interest, rising by 188.0% in August from 10,000 to 28,800 shares.
• Analysts have issued positive ratings for Inventiva, with Piper Sandler and HC Wainwright providing "overweight" and "buy" ratings along with target prices of $26.00 and $20.00, respectively.
• Institutional investors hold 19.06% of Inventiva's stock, with Wealth Enhancement Advisory Services recently increasing its stake by 54.5% in the second quarter.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totaling 28,800 shares, anincreaseof188.0% from the July 31st total of 10,000 shares. Based on an average trading volume of 24,800 shares, the short-interest ratio is presently 1.2 days. Based on an average trading volume of 24,800 shares, the short-interest ratio is presently 1.2 days.

Analyst Ratings Changes

A number of brokerages have commented on IVA. Piper Sandler began coverage on Inventiva in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 target price for the company. HC Wainwright began coverage on Inventiva in a research note on Wednesday. They issued a "buy" rating and a $20.00 target price for the company. Finally, Guggenheim lifted their target price on Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $14.83.

Institutional Investors Weigh In On Inventiva

A hedge fund recently raised its stake in Inventiva stock. Wealth Enhancement Advisory Services LLC increased its position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,558 shares of the company's stock after purchasing an additional 5,843 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 at the end of the most recent quarter. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $5.37 on Thursday. Inventiva has a 12 month low of $1.53 and a 12 month high of $6.50. The stock's 50 day moving average price is $3.80 and its 200 day moving average price is $3.42.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.